peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
Hansa Biopharma
HNSA (, %) SEK
Hansa Biopharma

Notice of Annual General Meeting in Hansa Medical AB (publ)

28 Mar 2013, 08:55
Regulatory information
Shareholders in Hansa Medical AB (publ) are hereby given notice of the Annual General Meeting on Monday, 6 May 2013, 5:00 pm (17:00), to be held in the lecture theatre at the company’s premises on Scheelevägen 22 in Lund. Doors open at 4.30 pm (16.30). Light refreshments will be provided following the meeting.

The right to participate in the Annual General Meeting of shareholders is extended to those who are both entered in the share register, administered by Euroclear Sweden AB, as per 29 April 2013, and who have registered their intention to participate in the Annual General Meeting no later than 12 pm (12.00) on 30 April 2013. For a complete Notice of AGM (in Swedish only) including a proposed agenda, see below, or visit www.hansamedical.com.

Files

For further information, please contact:
Hansa Medical AB
Emanuel Björne, CEO
Mobile: 46 707 17 54 77
E-mail: emanuel.bjorne@hansamedical.com

Hansa Medical is a drug and diagnostics discovery company focused on inflammatory diseases. The company develops innovative biological pharmaceuticals and diagnostic methods both independently and in partnership with large, established companies. At present, the company is primarily undertaking three development projects: IdeS, EndoS and HMD-301. New development projects and product candidates generated through cooperation with medical academic research are continuously evaluated. The main shareholders of Hansa Medical are Bo Håkansson via Farstorps Gård AB, and Bengt Ågerup via Nexttobe AB. Hansa Medical is listed on NASDAQ OMX First North, and Remium Nordic AB is the company’s Certified Adviser.